PPBT — Purple Biotech Share Price
Last trade - 00:00- $6.81m
- -$0.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.21 | ||
| Price to Tang. Book | 1.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.4% | ||
| Return on Equity | -12.35% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Directors
- Eric Rowinsky CHM (64)
- Itzhak Israel CEO (39)
- Gil Efron DCE (52)
- Gil Ben-Menachem VBD (49)
- Avraham Ben-Tzvi GCN (47)
- Yisrael Gewirtz OTH (41)
- Bertrand Liang OTH
- Hadas Reuveni OTH (50)
- Michael Schickler OTH
- Robert Gagnon DRC (46)
- Suzana Nahum-Zilberberg DRC (50)
- Simcha Rock DRC (68)
- Ido Agmon IND (40)
- Steven Steinberg IND (56)
- Revital Stern-Raff IND (44)
- Ran Tzror IND (36)
- Arie Weber IND (69)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- August 12th, 1968
- Public Since
- September 3rd, 1978
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 567,781,000
- Address
- 4 Oppenheimer St., Science Park, REHOVOT, 7670104
- Web
- https://purple-biotech.com/
- Phone
- +972 39333121
- Auditors
- Somekh Chaikin, CPAs
Similar to PPBT
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 22:48 UTC, shares in Purple Biotech are trading at $2.40. This share price information is delayed by 15 minutes.
Shares in Purple Biotech last closed at $2.40 and the price had moved by -68.48% over the past 365 days. In terms of relative price strength the Purple Biotech share price has underperformed the S&P500 Index by -71.72% over the past year.
The overall consensus recommendation for Purple Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePurple Biotech does not currently pay a dividend.
Purple Biotech does not currently pay a dividend.
Purple Biotech does not currently pay a dividend.
To buy shares in Purple Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.40, shares in Purple Biotech had a market capitalisation of $6.81m.
Here are the trading details for Purple Biotech:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PPBT
Based on an overall assessment of its quality, value and momentum Purple Biotech is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Purple Biotech is $32.78. That is 1265.91% above the last closing price of $2.40.
Analysts covering Purple Biotech currently have a consensus Earnings Per Share (EPS) forecast of -$2.42 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Purple Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -42.48%.
As of the last closing price of $2.40, shares in Purple Biotech were trading -25.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Purple Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Purple Biotech's management team is headed by:
- Eric Rowinsky - CHM
- Itzhak Israel - CEO
- Gil Efron - DCE
- Gil Ben-Menachem - VBD
- Avraham Ben-Tzvi - GCN
- Yisrael Gewirtz - OTH
- Bertrand Liang - OTH
- Hadas Reuveni - OTH
- Michael Schickler - OTH
- Robert Gagnon - DRC
- Suzana Nahum-Zilberberg - DRC
- Simcha Rock - DRC
- Ido Agmon - IND
- Steven Steinberg - IND
- Revital Stern-Raff - IND
- Ran Tzror - IND
- Arie Weber - IND